Logo

TITAN Solidifies Place for Apalutamide in Metastatic CSPC

ARTICLES

TITAN Solidifies Place for Apalutamide in Metastatic CSPC


MEDSCAPE

PUBLISHED: 06 JUNE 2019


New data show efficacy for the next-generation androgen receptor inhibitor apalutamide (Erleada, Janssen) in the treatment of metastatic hormone-sensitive prostate cancer, which would be a new indication for the drug.

explore_now-footer.png


Published

June 6, 2019

Categories

Oncology
CP-202103